Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays.
Recommended Working Concentration: 0.005-1 μg/ml
Summary
Specifications
Antibody Isotype
IgG
Immunogen
Tocilizumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays. Recommended Working Concentration: 0.001-0.1 μg/ml
General Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays. Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration. It has a high affinity to IL-6R and blocks the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex. Tocilizumab is used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children.
Target
Alternative Names
Rabbit polyclonal antibody to Actemra; Tocilizumab; atlizumab
Citations
Publication ()
Have you cited CABT-ZB277 in a publication? Let us know and earn a reward for your research.
My Review for Rabbit Anti-Tocilizumab polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
